Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

 OxStem

OxStem Ltd, a University of Oxford spin-out company co-founded by Professor Steve Davies and Professor Angela Russell, is featured in the May 2017 issue of Nature in an article entitled “Masters of Medicine”. OxStem was selected as one of six innovative and disruptive University start-up biotechnology companies from around the world to be profiled in the article. Read more…

Similar stories

Modernized Oxford anti-arrhythmic drug classification gains global recognition as the new standard in antiarrhythmic drug clinical guidelines

Cardiac arrhythmias pose a serious global health challenge. The commonest sustained arrhythmia atrial fibrillation (AF) affects 1–2% of the worldwide population. Antiarrhythmic drugs (AADs) remain central to their pharmacotherapeutic management. As a solution, Professors Ming Lei, Derek Terrar (both Pharmacology), Christopher Huang (University of Cambridge), and Lin Wu (Beijing University Hospital) developed and proposed the 2018 Oxford modernized antiarrhythmic drug (AAD) classification (Circulation, 2018;138:1879–1896).